Please login to the form below

Not currently logged in
Email:
Password:

balugrastim

This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.

EMA backs 15 new medicines for use in EU

EMA backs 15 new medicines for use in EU

tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    Teva withdraws US filing for cancer biologic. FDA requests more data for balugrastim. ... Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim.

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics